Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QWINT-4: Insulin Efsitora Alfa vs Glargine in T2D on Basal-Bolus
NCT05462756Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2022
- Primary completion
- Feb 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 8
01
Overview
A Phase 3 trial of Insulin efsitora alfa in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Aug 2022; status: completed.
02
Drugs
Insulin efsitora alfa
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05462756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05462756.